Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20955932 | 1.00 | NR3C1 (0.36) | NR3C1PGRARKDM4EMEN1 | |
| SCHEMBL19863577 | 0.86 | ALDH1A1 (0.53) | KDM4EMEN1KMT2ASYKALDH1A1 | |
| SCHEMBL29595384 | 0.81 | HTT (0.39) | NR3C1PGRARALDH1A1MAPT | |
| SCHEMBL29798910 | 0.81 | HTT (0.39) | NR3C1PGRARALDH1A1MAPT | |
| SCHEMBL19863579 | 0.81 | HTT (0.39) | NR3C1PGRARALDH1A1MAPT | |
| SCHEMBL5748532 | 0.76 | PDE4B (0.44) | MEN1KMT2ASYKPDE4B | |
| SCHEMBL15249748 | 0.76 | SYK (0.51) | MEN1KMT2ASYKPDE4B | |
| SCHEMBL23948514 | 0.75 | PDE4B (0.48) | MEN1KMT2ASYKPDE4B | |
| SCHEMBL23948144 | 0.75 | IRAK4 (0.38) | MEN1KMT2ASYKPDE4B | |
| SCHEMBL1226594 | 0.73 | MEN1 (0.49) | MEN1KMT2ASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800783-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800783-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | NR3C1 1588/4885PGR 210/4885AR 986/4885 |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | NR3C1 1588/4885PGR 210/4885AR 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.